The effects of the novel SHIP1 activator AQX‐1125 on allergen‐induced responses in mild‐to‐moderate asthma
暂无分享,去创建一个
F. Ali | P. Barnes | B. O'connor | B. Leaker | P. Tam | J. Neville | L. Mackenzie | T. MacRury | P. J. Barnes | F. Ali
[1] N. Gross. The COPD Pipeline XXVII. , 2015, Chronic obstructive pulmonary diseases.
[2] M. Silkey,et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen‐induced airway responses in allergic asthmatics , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[3] C. Szabó,et al. Characterization of AQX‐1125, a small‐molecule SHIP1 activator , 2013, British journal of pharmacology.
[4] C. Szabó,et al. Characterization of AQX‐1125, a small‐molecule SHIP1 activator , 2013, British journal of pharmacology.
[5] R. Parry,et al. Fine tuning T lymphocytes: a role for the lipid phosphatase SHIP-1. , 2010, Biochimica et biophysica acta.
[6] Dave Singh,et al. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma , 2010, Respiratory research.
[7] P. O'Byrne. Allergen-induced airway inflammation and its therapeutic intervention , 2009, Allergy, asthma & immunology research.
[8] C. Mitchell,et al. The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease. , 2009, The Biochemical journal.
[9] D. Spina,et al. PDE4 inhibitors: current status , 2008, British journal of pharmacology.
[10] P. Barnes. Immunology of asthma and chronic obstructive pulmonary disease , 2008, Nature Reviews Immunology.
[11] A. Woodcock,et al. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. , 2007, American journal of respiratory and critical care medicine.
[12] S. Wenzel,et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies , 2007, The Lancet.
[13] David E. Williams,et al. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. , 2007, Blood.
[14] Lewis C. Cantley,et al. AKT/PKB Signaling: Navigating Downstream , 2007, Cell.
[15] M. Conti,et al. Differential Expression and Function of Phosphodiesterase 4 (PDE4) Subtypes in Human Primary CD4+ T Cells: Predominant Role of PDE4D1 , 2007, The Journal of Immunology.
[16] P. O'Byrne,et al. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. , 2007, The Journal of allergy and clinical immunology.
[17] W. Busse,et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study , 2006, BMC pulmonary medicine.
[18] P. Bardin,et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. , 2005, The Journal of allergy and clinical immunology.
[19] D. Postma,et al. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. , 2005, The Journal of allergy and clinical immunology.
[20] J. Cowan,et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. , 2005, The New England journal of medicine.
[21] J. Lötvall,et al. Differential effects of fluticasone and montelukast on allergen‐induced asthma , 2005, Allergy.
[22] R. Pauwels,et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.
[23] G. Krystal,et al. The Inositol 5′-Phosphatase SHIP-1 and the Src Kinase Lyn Negatively Regulate Macrophage Colony-stimulating Factor-induced Akt Activity* , 2003, Journal of Biological Chemistry.
[24] S. Anderson,et al. Indirect airway challenges , 2003, European Respiratory Journal.
[25] H. Magnussen,et al. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma , 2002, European Respiratory Journal.
[26] K. Ravichandran,et al. Regulation of the immune response by SHIP. , 2002, Seminars in immunology.
[27] P. O'Byrne,et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. , 2001, American journal of respiratory and critical care medicine.
[28] G. Krystal,et al. Lipid phosphatases in the immune system. , 2000, Seminars in immunology.
[29] G. Krystal,et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. , 1998, Genes & development.
[30] S. Holgate,et al. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. , 1997, The European respiratory journal.
[31] R. Pauwels,et al. GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .
[32] F. Hargreave,et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. , 1996, American journal of respiratory and critical care medicine.